Yung-Jue Bang

Yung-Jue Bang is a distinguished medical oncologist who has led landmark NSCLC trials in Asian populations, including pivotal ALK inhibitor studies. He contributed to the global PROFILE trial program evaluating crizotinib and subsequent generation inhibitors across diverse patient populations. His extensive research on biomarker-selected lung cancer therapies has informed treatment guidelines throughout Asia and globally. He has mentored generations of Asian oncologists and holds honorary positions at numerous international societies.